University of Ulm   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ulm Germany (1967)

Organization Overview

First Clinical Trial
1992
NCT01060501
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Abdenour Nabid | Albert Christian Ludolph, Prof. | AMLSG Clinical Trials Office | B. Höchsmann | Bundeswehrkrankenhaus Ulm | Christian Buske | Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm | Coordinating Investigator Germany University Hospital Ulm | Department of Gynecology and Obstetrics, University Hospital Ulm, Germany | Department of Internal Medicine III, University of Ulm | Department of Neurology, University of Ulm | Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Ulm, Germany | Division of Nephrology, University Hospital of Ulm | Division of Nephrology, University Hospital Ulm | Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany | Medical Center University of Ulm | Olgahospital, CWS | Olga Hospital Stuttgart, Germany | Pediatric Urology, Department for Urology University of Ulm, Germany | Prof. Dr. Rainer Muche, Dr. Jens Dreyhaupt, Institute of Epidemiology and Medical Biometry, University of Ulm | Prof. W. Janni | Radicle Science, Inc | Studienzentrale Dpt. Gyn/OB University Ulm | Ulm University | Ulm University Hospital | Ulm University Hospital, Department of Internal Medicine I | Universitaetsklinikum Ulm | UNIVERSITAET ULM (UULM) | Universitat Ulm | Universitiy of Ulm School of Medicine | University Hospital of Ulm | University Hospital Ulm | University Hospital Ulm -Department of Gynecology | University Hospital Ulm, Department of Internal Medicine II | University Hospital Ulm Department of Internal Medicine III | University Hospital, Umeå | University Medical Center Ulm | University of Ulm | University of Ulm / Department of Internal Medicine III | University of Ulm, Dept. of Internal Medicine I | University of Ulm, Dept. of Visceral Surgery | University of Ulm, Germany | University of Ulm, Germay | University of Ulm, Medical Center, Ulm, Germany | University Ulm

Active Ingredients

Drugs in Phase 4 Trials (20)

abemaciclib (verzenio) (1 trial)

atropine (1 trial)

cisplatin (platinol) (3 trials)

dabigatran (pradaxa) (1 trial)

dobutamine (dobutrex) (1 trial)

dopamine (intropin) (1 trial)

ertapenem (invanz) (1 trial)

fentanyl (Innovar) (1 trial)

fluorouracil (efudex) (2 trials)

fulvestrant (faslodex) (2 trials)

interferon alpha-2b (Intron-A) (2 trials)

lamivudine (epivir) (1 trial)

mitomycin (mutamycin) (1 trial)

mivacurium (mivacron) (1 trial)

moxifloxacin (avelox) (1 trial)

phenprocoumon (liquamar) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

ribavirin (virazole) (1 trial)

telbivudine (tyzeka) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 3 Trials (46)

abciximab (Reopro) (1 trial)

allogeneic stem cells (2 trials)

anastrozole (arimidex) (2 trials)

autologous bone marrow derived mesenchymal cells (2 trials)

azithromycin (zithromax) (1 trial)

bicalutamide (casodex) (1 trial)

bortezomib (velcade) (1 trial)

bupropion (wellbutrin) (2 trials)

capecitabine (xeloda) (2 trials)

carfilzomib (kyprolis) (1 trial)

crenolanib (1 trial)

cyclophosphamide (cytoxan) (4 trials)

cytarabine (cytosar-u) (15 trials)

dasatinib (sprycel) (2 trials)

daunorubicin (cerubidine) (6 trials)

defibrotide (defitelio) (1 trial)

docetaxel (taxotere) (4 trials)

doxorubicin (Doxil) (1 trial)

eltrombopag (promacta) (2 trials)

etoposide (vepesid) (8 trials)

exemestane (aromasin) (2 trials)

ferric carboxymaltose (Injectafer) (1 trial)

Filgrastim (neupogen) (1 trial)

fludarabine (fludara) (2 trials)

gemtuzumab ozogamicin (mylotarg) (2 trials)

goserelin (zoladex) (1 trial)

ibrutinib (imbruvica) (3 trials)

idarubicin (idamycin) (6 trials)

ifosfamide (ifex) (1 trial)

lapatinib (tykerb) (1 trial)

letrozole (femara) (2 trials)

leucovorin (1 trial)

mitoxantrone (novantrone) (4 trials)

nivaldipine (1 trial)

paclitaxel (taxol) (4 trials)

pertuzumab (perjeta) (2 trials)

riluzole (rilutek) (1 trial)

rituximab (rituxan) (5 trials)

sargramostim (leukine) (3 trials)

tamoxifen (nolvadex) (1 trial)

trastuzumab (herceptin) (2 trials)

tretinoin (Retin-A) (5 trials)

urea (3 trials)

ursodeoxycholic acid (2 trials)

venetoclax (venclexta) (3 trials)

vinorelbine (navelbine) (3 trials)

Drugs in Phase 2 Trials (47)

aflibercept (zaltrap) (1 trial)

alemtuzumab (campath) (3 trials)

allogeneic adipose derived mesenchymal stem cell (2 trials)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

amitriptyline (elavil) (1 trial)

autologous hematopoietic stem cells (1 trial)

autologous mesenchymal stem cells (1 trial)

autologous muscle derived stem cells (1 trial)

azacitidine (vidaza) (2 trials)

beta-hydroxybutyrate (1 trial)

bone autograft (1 trial)

cabazitaxel (jevtana kit) (1 trial)

carmustine (bicnu) (1 trial)

copanlisib (aliqopa) (1 trial)

copper (cu-7) (1 trial)

dexamethasone (1 trial)

disulfiram (antabuse) (2 trials)

enzalutamide (xtandi) (1 trial)

eribulin (halaven) (1 trial)

esketamine (spravato) (1 trial)

everolimus (zortress) (1 trial)

gemcitabine (gemzar) (2 trials)

immune globulin (human) (Gamastan) (1 trial)

l-epigallocatechin (1 trial)

lomustine (1 trial)

mannitol (Osmitrol) (1 trial)

melphalan (alkeran) (1 trial)

mesna (mesnex) (1 trial)

methadone (methadose) (1 trial)

midostaurin (rydapt) (1 trial)

naltrexone (revia) (1 trial)

obinutuzumab (gazyva) (2 trials)

ofatumumab (arzerra) (1 trial)

oxaliplatin (eloxatin) (1 trial)

palbociclib (ibrance) (1 trial)

pembrolizumab (keytruda) (2 trials)

pioglitazone (actos) (1 trial)

pomalidomide (pomalyst) (2 trials)

prednisone (meticorten) (1 trial)

procarbazine (matulane) (1 trial)

rasagiline (azilect) (1 trial)

ruxolitinib (jakafi) (1 trial)

temozolomide (temodar) (2 trials)

temsirolimus (torisel) (1 trial)

trastuzumab emtansine (kadcyla) (1 trial)

volasertib (1 trial)

vosaroxin (1 trial)

Drugs in Phase 1 Trials (13)

18f-mni-659 (1 trial)

aadvac1 (1 trial)

acetaminophen (tylenol) (1 trial)

aprepitant (Emend) (1 trial)

auranofin (ridaura) (1 trial)

captopril (capoten) (1 trial)

celecoxib (celebrex) (1 trial)

ibuprofen (motrin) (1 trial)

itraconazole (sporanox) (1 trial)

lenalidomide (revlimid) (1 trial)

minocycline (minocin) (1 trial)

ritonavir (Norvir) (1 trial)

sertraline (zoloft) (1 trial)

Drugs in Other Trials (9)

atorvastatin (lipitor) (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

darbepoetin beta (1 trial)

ethanol (1 trial)

ferrous sulfate (2 trials)

icosapent ethyl (vascepa) (2 trials)

long-chain triglyceride (1 trial)

oxygen (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenoma (Phase 2)

Adenoma, Villous (Phase 2)

Alzheimer Disease (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Anemia (Phase 3)

Anemia, Aplastic (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Anemia, Refractory (Phase 3)

Anemia, Refractory, with Excess of Blasts (Phase 3)

Aphasia (Phase 1)

Aphasia, Broca (Phase 1)

Aphasia, Primary Progressive (Phase 1)

Atrial Fibrillation (Phase 4)

Atrophy (Phase 3)

Breast Neoplasms (Phase 3)

Bronchopulmonary Dysplasia (Phase 3)

Colonic Neoplasms (Phase 4)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronavirus Infections (Phase 2)

Cystic Fibrosis (Phase 2)

Dementia (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diverticular Diseases (Phase 4)

Diverticulosis, Colonic (Phase 4)

Diverticulum (Phase 4)

Fibrosis (Phase 2)

Frontotemporal Dementia (Phase 1)

Glioblastoma (Phase 2)

Heart Failure (Phase 3)

Hepatic Veno-Occlusive Disease (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Histiocytoma (Phase 3)

Histiocytoma, Benign Fibrous (Phase 3)

Histiocytoma, Malignant Fibrous (Phase 3)

Huntington Disease (Phase 2)

Hypotension (Phase 4)

Infarction (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Liver Diseases (Phase 4)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Motor Neuron Disease (Phase 3)

Multiple System Atrophy (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 4)

Neoplastic Cells, Circulating (Phase 3)

Oropharyngeal Neoplasms (Phase 4)

Osteoarthritis (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pick Disease of the Brain (Phase 1)

Pneumonia (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 2)

Primary Progressive Nonfluent Aphasia (Phase 1)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 4)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Sclerosis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Shy-Drager Syndrome (Phase 3)

ST Elevation Myocardial Infarction (Phase 3)

Supranuclear Palsy, Progressive (Phase 3)

Syndrome (Phase 2)

Thrombocytopenia (Phase 2)

Thrombosis (Phase 4)

Tinnitus (Phase 2)

Virus Diseases (Phase 4)

Waldenstrom Macroglobulinemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 103
  • # of Trial APIs: 135